Benzinga | Oct 6, 2021 07:04AM EDT

RedHill Biopharma Ltd Announces Talicia(R) Added To Medi-Cal CDL

RedHill Biopharma's Talicia(r) added to Medi-Cal Contract Drug List with No Prior Authorization Requirements

Addition of Talicia(r) by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization is an important expansion of coverage for California patients and continues to increase Talicia's overall unrestricted coverage

Coverage commenced for two million patients in Medi-Cal's FFS plan on October 1st, 2021

Talicia(r) is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies

H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population